- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 91,290 | 23.05.24 15:49:59 | -0,510 | -0,56% | 90,570 | 90,750 | 92,620 | 91,800 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 916,800 | 23.05.24 10:56:15 | +6,800 | +0,75% | 906,600 | 912,800 | 904,400 | 910,000 |
